Jul 29, 2010 · PA2024 consists of a prostate antigen, prostatic acid phosphatase, that is fused to granulocyte–macrophage colony-stimulating factor, an immune-cell activator.

revenue.pa.gov PA-40 3 PA DEPARTMENT OF REVENUE DISTRICT OFFICES NOTE: Please call ahead to verify a district office’s address and its services. Visit the department’s website at revenue.pa.gov for more information. Taxpayer assistance hours are from 8:30 AM to 5:00 PM.

PA2024 is a recombinant protein of PAP fused at its carboxyl terminus to the amine terminus of granulocyte-macrophage colony-stimulating factor (GM-CSF) via a glycine-serine link . PAP is the ultimate target TAA; GM-CSF facilitates immune activation by enhancing APC recognition and uptake [12, 13]. After the PBMCs have been centrifuged and ...

prostatic acid phosphatase-sargramostim fusion protein PA2024 A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor ...

Mar 4, 2025 · This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating ...

Mar 20, 2017 · Cancer-specific immunoglobulins directed at granulocyte-macrophage-colony-stimulating factor/prostatic acid phosphatase (PAP) fusion protein (PA2024) and PAP were measured prior to SIP-T, after SIP-T, 1 week after IPI, every other month for 5 months, then every 3 months for an additional 12 months.

Jan 1, 2019 · Sipuleucel-T is an active cellular immunotherapy consisting of autologous, peripheral blood mononuclear cells (PBMC's), including antigen presenting cells (APC's) that have been activated in vitro with a recombinant fusion protein (PA2024).

The 2024 United States presidential election in Pennsylvania took place on Tuesday, November 5, 2024, as part of the 2024 United States presidential election in which all 50 states plus the …

May 13, 2021 · Luminex assay for anti-prostatic acid phosphatase (PAP) and anti-PA2024-specific serum immunoglobulin G (IgG) and ELISpot for interferon-γ (IFN-γ) production against PAP and PA2024 were used to assess antigen-specific B and T cell responses, respectively.

Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient’s own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer.